Full Breakdown
Eli Lilly to Acquire Ajax Therapeutics in $2.3 B Deal Targeting Blood-Cancer Therapies
4/28/2026, 5:24:37 AM
Deal Overview and Core Asset
Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. for up to $2.3 billion in cash. The consideration combines an upfront payment with milestone-based payments tied to clinical and regulatory achievements. The transaction, subject to antitrust clearance under the Hart-Scott-Rodino Act, will transfer all outstanding Ajax shares to Lilly. The centerpiece of the deal is AJ1-11095, a first-in-class, once-daily oral Type II JAK2 inhibitor currently in a Phase 1 trial (AJX-101) for patients with myelofibrosis who have previously received a Type I JAK2 inhibitor. Proof-of-concept data are slated for release later in 2026, with dose selection expected the same year.
Background and Context
Ajax was founded in 2019 to develop next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs), a group of rare blood cancers that includes myelofibrosis and polycythemia vera. Existing JAK2 inhibitors bind the Type I conformation of the kinase and often lose efficacy, leading to treatment discontinuation. Lilly has used cash flow from its blockbuster diabetes and obesity drugs to fund a series of oncology acquisitions—Scorpion Therapeutics, Orna Therapeutics, Kelonia Therapeutics, CrossBridge Bio, and now Ajax—to broaden its pipeline beyond solid-tumor indications and into hematologic malignancies.
Key Figures and Organizations
- Jacob Van Naarden – Executive Vice President, President of Lilly Oncology, and Head of Corporate Business Development.
- Martin Vogelbaum – Co-founder and Chief Executive Officer of Ajax Therapeutics.
- Ross Levine, MD – Chief Scientific Officer at Memorial Sloan Kettering Cancer Center and chair of Ajax’s Scientific Advisory Board.
- Schrödinger, Inc. – Computational-structure-based drug-discovery partner cited by Ajax.
- Legal counsel: Ropes & Gray (Lilly); Cooley LLP and Kirkland & Ellis LLP (Ajax).
Data and Statistics
- Transaction value: up to $2.3 billion (some reports cite a potential $3 billion sum).
- AJ1-11095: first-in-class Type II JAK2 inhibitor, oral, once-daily dosing.
- Clinical status: Phase 1 trial initiated late 2024; proof-of-concept data expected 2026.
- Regulatory status: orphan-drug designation from the U.S. FDA.
- Ajax’s locations: Cambridge, Massachusetts, and New York City.
Why It Matters
If AJ1-11095 demonstrates durable efficacy, it could address the unmet need of patients whose disease progresses on existing Type I JAK2 inhibitors. The acquisition expands Lilly’s hematology portfolio, diversifying revenue away from its GLP-1-based obesity and diabetes products and positioning the company to compete in the blood-cancer market. Analysts note the deal “builds on Lilly’s established capabilities in blood cancers and helps expand its future commercial products beyond obesity.”
Official Statements & Responses
Lilly’s Van Naarden emphasized the company’s belief in Ajax’s approach and its intent to move AJ1-11095 rapidly into registrational trials. Vogelbaum highlighted Ajax’s scientific foundation, the work of its five founders, and the goal of delivering a “much-needed new therapy for patients with MPNs.” The press release includes standard forward-looking cautions about the uncertainties of closing the transaction and achieving clinical milestones.
Criticism & Opposition
The supplied sources do not contain any public criticism or dissenting viewpoints regarding the acquisition.
Conflicting Reports & Gaps
- Financial amount: Most sources state a maximum of $2.3 billion, while a Biospace report references a “$3 billion potential sum.”
- Milestone details: Exact timing and criteria for milestone payments are not disclosed.
Verbatim Quotes
- “As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings,” — Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, Eli Lilly and Company
- “ Jacob Van Naarden, Executive Vice President And President Of Lilly Oncology And Head Of Corporate Business Development, Eli Lilly and Company “We started Ajax to build on the work of its five scientific founders, including Ross Levine, MD, chief scientific officer at Memorial Sloan Kettering Cancer Center and chair of Ajax’s scientific advisory board, who sought to develop a novel class of selective and more potent JAK2 inhibitors to address the significant unmet need of patients with MPNs.” — Martin Vogelbaum, Co-Founder and Chief Executive Officer, Ajax Therapeutics
- “could offer a competitive therapy in MPNs where traditional JAK inhibitors have failed,” — Evan Seigerman, BMO Analyst
- “builds on Lilly’s established capabilities in blood cancers and helps expand its future commercial products beyond obesity.” — Louise Chen, Scotiabank Analyst
What’s Next
Lilly expects to receive proof-of-concept data later in 2026, select a Phase 2 dose the same year, and advance AJ1-11095 into registrational trials. Completion of the acquisition awaits customary regulatory approvals and antitrust clearance. Successful development could lead to a new therapeutic option for myelofibrosis and polycythemia vera patients resistant to existing JAK2 inhibitors.
